3 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 3, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Down Syndrome: new trials by email Literature Review of Down Syndrome trials Research Report on Down Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation Donanemab, Placebo - Down Syndrome (DS), Down Syndrome (Trisomy 21) | Phase 4 | Not yet recruiting | Michael Rafii, MD, PhD | 60 | 2026-08-01 | 2026-05-15 |
| Endotype DIrected Treatment for OSA in Down Syndrome ato-oxy, Oxygen - Obstructive Sleep Apnea (OSA), Down Syndrome | Phase 4 | Recruiting | University of Arizona | 200 | 2026-03-14 | 2026-09-03 |
| Fluoxetine Treatment of Depression in Down Syndrome Fluoxetine - Down Syndrome, Depression | Phase 4 | Completed | Massachusetts General Hospital | 4 | 2022-12-05 | 2025-03-30 |
| Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients Liquid stable levothyroxine (L-T4) Tirosint-SOL, Oral tablet levothyroxine (L-T4) - Hypothyroidism, Trisomy 21 | Phase 4 | Terminated | Children's Mercy Hospital Kansas City | 6 | 2021-01-18 | 2023-09-13 |
| Evaluating Treatment of ADHD in Children With Down Syndrome Quillivant XR, Placebo - Down Syndrome, ADHD | Phase 4 | Completed | Children's Hospital Medical Center, Cincinnati | 44 | 2020-10-02 | 2026-11-02 |
| Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome Memantine, Placebo - Down Syndrome | Phase 4 | Completed | University of Colorado, Denver | 42 | 2008-07-01 | 2013-02-01 |
Alzheimer Disease (1) · Attention Deficit Disorder with Hyperactivity (1) · Depression (1) · Hypothyroidism (1) · Plaque, Amyloid (1) · Sleep Apnea, Obstructive (1)
Abnormalities, Multiple (6) · Chromosome Disorders (6) · Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Intellectual Disability (6) · Nervous System Diseases (6) · Neurobehavioral Manifestations (6) · Neurologic Manifestations (6) · Mental Disorders (2) · Apnea (1) · Attention Deficit and Disruptive Behavior Disorders (1) · Behavior (1) · Behavioral Symptoms (1) · Brain Diseases (1)
Atomoxetine Hydrochloride (1) · Fluoxetine (1) · Memantine (1) · Methylphenidate (1) · Oxygen (1) · Thyroxine (1) · donanemab (1) · oxybutynin (1)
Children's Hospital Medical Center, Cincinnati (1) · Children's Mercy Hospital Kansas City (1) · Massachusetts General Hospital (1) · Michael Rafii, MD, PhD (1) · University of Arizona (1) · University of Colorado, Denver (1)
United States (5)
Alberto Costa, MD, Ph.D (1) · Anna Esbensen, PhD (1) · Benjamin Handen, MD (1) · Daniel Combs, MD (1) · Edward Goldson, MD (1) · Kathleen Angkustsiri, MD (1) · Michael Rafii, MD, PhD (1) · Robyn P. Thom, MD (1) · Sabrina Sargado, MD (1) · Tanya Froehlich, MD (1)
R33AG066543 (1)